|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 813 JPY | +0.62% |
|
-1.45% | -30.63% |
| Mar. 21 | US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak | MT |
| Mar. 21 | JCR Pharmaceuticals Achieves Neurodegenerative Treatment Research Milestone With Alexion | MT |
Astrazeneca said on Friday it is beginning Phase 1/2 clinical trials in Japan of its coronavirus vaccine candidate.
Trials of the vaccine, known as AZD1222, will be conducted at multiple facilities in Japan, targeting 250 subjects, the company said in a release.
The British company is working with Daiichi Sankyo, JCR Pharma and other partners in Japan to make and distribute the vaccine.
(Reporting by Rocky Swift and Chris Gallagher in Tokyo; Editing by Tom Hogue)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 11,352 GBX | +0.75% | +4.51% | 217B | ||
| 4,729 JPY | +1.42% | +3.80% | 57.77B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -30.63% | 652M | |
| +26.31% | 672B | |
| +25.87% | 570B | |
| -5.34% | 360B | |
| +16.26% | 321B | |
| +8.59% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.87% | 149B |
JCR PHARMACEUTICALS CO., LTD. 
